[#DIV28SUPER] NIDA Neuroscience Update, March 4, 2021

Table of Contents

I.                   Job Opening (Formulation of Drug Product - Chemist) at NIDA Headquarters - Rockville, Maryland

II.                 NIDA Data Career Seminar Series

III.              Some Recent NIDA Funding Opportunities (FOAs)

 

I.               Job Opening (Formulation of Drug Product -  Chemist) at NIDA Headquarters - Rockville, Maryland

The Division of Therapeutics and Medical Consequences (DTMC) supports and conducts studies to evaluate the safety and efficacy of new pharmacotherapies, behavioral therapies, devices, and digital therapeutics to treat Substance Use Disorders (SUDs). DTMC supports research and development for all stages of the medication development process.

 

Chemistry and Pharmaceutics: The incumbent is responsible for managing a research program of grants and contracts evaluating chemical design, synthesis, formulation, metabolism, pharmacokinetic and pharmacodynamic, and biopharmaceutics.  While not exclusive to, the focus of this position is the formulation of drug products, which includes design, manufacturing, quality control, packaging, labeling, storage and stability.  If interested:  Please submit your cover letter, and CV to Dr. Rik Kline (rkline@nida.nih.gov) 301-827-5243.  All information provided by candidates will remain strictly confidential.  Selection for this position is dependent upon successful referral from the USAJOBS vacancy announcement (TBA).  A candidate with a Ph.D in a relevant discipline is strongly desired (salary range is between $86,335 to $157,709).

 

 

II.             NIDA Data Career Seminar Series

NIDA will be hosting a 4-part Data Science careers seminar series this spring titled Bringing Data Science to Addiction Research. The goal of this seminar series is to highlight the career paths of prominent data scientists and inspire a new generation of data science researchers who focus on addiction. This series will take place on the following dates from 9:00-10:30am EDT (Please note that this is during Daylights Savings Time): March 15th, March 22nd, March 29th, and April 5th. A separate registration will be required for each session.

Contact Dr. Susan Wright at susan.wright@nih.gov with any questions.

This series will kick off with a fireside chat with Dr. DJ Patil (Twitter: @dpatil), the former U.S. Chief Data Scientist, on March 15h from 9:00-10:30am EST. Register for this session at: https://bit.ly/3kEHw7c

 

III.            Recent NIDA FOAs:

 

Notice of Special Interest (NOSI): Human Molecular Genetics of Substance Use Disorder Notice Number: NOT-DA-20-030     Application due date: Standard dates apply                                                                                                                                                   

High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 - Clinical Trials Not Allowed) RFA-DA-22-006  Application due date: Standard dates apply                                                                                                                                                   

Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01- Clinical Trial Optional) RFA-DA-22-010 Application due dates: October 25, 2021 and October 25, 2022 by 5:00 PM local time of applicant organization.

 

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) PAR-20-225 (DP1) Application due dates: October 19, 2021, October 19, 2022 by 5:00 PM local time of applicant organization.

 

Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional) PAR-20-224 (DP2)   Application due dates: August 13, 2020, August 13, 2021, August 15, 2022 by 5:00 PM local time of applicant organization.

 

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)

RFA-DA-22-004 (R61/R33) Application due dates: July 14, 2021 and July 14, 2022 by 5:00 PM local time of applicant organization.

 

NIH Blueprint for Neuroscience Research: Tools and Technologies to Explore Nervous System Biomolecular Condensates (R21 Clinical Trial Not Allowed) RFA-DA-22-008 Application due date: September 15, 2021 by 5:00 PM local time of applicant organization.

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L